CVM — what changed in the latest 10-Q
A section-by-section comparison of CVM's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +4 | −2 | ~14 | 67 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 0 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings, Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
An “unmet (medical) need” is a factor for approval that is usually considered by all major regulatory bodies worldwide when assessing a product for commercial licensing. Despite some advances in treating patients with advanced primary squamous cell carcinoma of the head and neck there is still a sig…
Pembrolizumab (Keytruda) was approved only as a combination therapy – given as neoadjuvant (before surgery) and after surgery along with radiotherapy +/- chemotherapy and then long term. It was approved for perioperative use based on Event Free Survival only, not Overall Survival. Further, Keytruda …
Multikine could potentially increase that survival rate to over 70% in the patient population targeted in the confirmatory clinical trial of Multikine which is based on data obtained from the completed Multikine Phase III trial. In contrast to Keytruda, Multikine is given to newly diagnosed resectab…
During the nine months ended June 30, 2026, the Company’s cash decreased by approximately $4.4 million. The significant components of this decrease included net proceeds from the purchase of stock by officers and the June 2026 financing of $9.3 million offset by cash used to fund the Company’s regul…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
During the six months ended March 31, 2025, 247,583 pre-funded warrants were exercised. No warrants were exercised during the six months ended March 31, 2026.
During the six months ended March 31, 2025, the Company’s cash decreased by approximately $2.8 million. Significant components of this decrease included net proceeds from the December 2024 and March 2025 financing of $6.7 million offset by cash used to fund the Company’s regular operations of approx…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice